Cancer Treatment is HARD!

| January 7, 2019

article image
Drug development – it’s an area rife with risk, but with great risk often comes great rewards. An area notoriously prone to failure is oncology, and nowhere is accurate risk assessment more critical. Developing Cancer Treatments is HARD! But is everyone bad at it? is a view into this failure-prone area from Pharmapremia.

Spotlight

Ethiopian Pharmaceutical Manufacturing Sh. Co.

The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

OTHER ARTICLES

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 25, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Top Specialty Pharmacy Therapy Areas

Article | February 25, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | February 25, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

Ethiopian Pharmaceutical Manufacturing Sh. Co.

The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

Events